Premium
Benefit of palliative chemotherapy and hospice enrollment in late‐stage ovarian cancer patients
Author(s) -
Tsubamoto Hiroshi,
Ito Yoshihiro,
Kanazawa Riichiro,
Wada Ryu,
Hosoda Yoko,
Honda Okuto,
Takeyama Ryu,
Sakane Riya,
Wakimoto Yu,
Shibahara Hiroaki
Publication year - 2014
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12320
Subject(s) - medicine , chemotherapy , taxane , hazard ratio , stage (stratigraphy) , ovarian cancer , multivariate analysis , oncology , palliative chemotherapy , palliative care , cancer , confidence interval , nursing , breast cancer , paleontology , biology
Aim The ideal timing for transition to best supportive care ( BSC ) for ovarian cancer patients is not clear. We retrospectively assessed the survival benefit of continuing chemotherapy and hospice enrollment in late‐stage ovarian cancer patients. Materials and Methods Eligibility criteria included platinum and taxane treatment, clinical progression within 6 months of the last platinum dose, and progression during chemotherapy. Results Of the 55 eligible patients (median overall survival after first becoming refractory [1st R ef], 96 days), 22 received chemotherapy ( C hemo group), two received radiation therapy, and 13 had medical contraindications for subsequent chemotherapy. The remaining 18 patients ( BSC group) were compared with the C hemo group. The C hemo and BSC groups had similar background characteristics, except for the rate of consultation with a regional palliative care physician before or within 1 week of 1st R ef (9% vs 50%, respectively). In multivariate analysis, chemotherapy (hazard ratio 0.251, P = 0.005) and hospice enrollment (hazard ratio, 0.274, P = 0.023) were predictive factors of survival after 1st R ef. Conclusions Chemotherapy after 1st R ef can be offered and hospice enrollment during the terminal stages is encouraged for recurrent ovarian cancer patients.